METX — ME Therapeutics Holdings Income Statement
0.000.00%
Last trade - 00:00- CA$124.69m
- CA$123.34m
Annual income statement for ME Therapeutics Holdings, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 0.105 | 0.071 | 0.163 | 6.55 |
| Operating Profit | -0.105 | -0.071 | -0.163 | -6.55 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -0.052 | -0.071 | -0.146 | -6.52 |
| Net Income After Taxes | -0.052 | -0.071 | -0.146 | -6.52 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.052 | -0.071 | -0.146 | -6.52 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.052 | -0.071 | -0.146 | -6.52 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.002 | -0.003 | -0.006 | -0.04 |
| Dividends per Share |